tailieunhanh - Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain

Due to economic constraints, cancer therapies are under close scrutiny by clinicians, pharmacists and payers alike. There is no published pharmacoeconomic evidence guiding the choice of first-line therapy for advanced renal cell carcinoma (RCC) in the Spanish setting. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN